RxDoctor Payments DataLook up a doctor →

Brandon McLin, PA

Physician Assistant · Maryville, TNNPI 1821450750

Payments from drug & device makers

$13,413in general payments, 2019–2025

Across 694 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Insmed, Inc.$1K
  • Harmony Biosciences LLC$913
  • Boehringer Ingelheim$859
  • United Therapeutics Corporation$757
  • plus $6K from 32 others

What the payments were for

  • Food & beverage$13,16898%
  • Education$2442%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,413 in reported general payments places this provider in the 95th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$67,501
Medicare patients
513
Services billed
995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter201$285,038
Breztri AerosphereBudesonide/Glycopyr/Formoterol44$56,214
Stiolto RespimatTiotropium Br/Olodaterol Hcl48$43,973
Breo ElliptaFluticasone/Vilanterol53$37,329
Spiriva RespimatTiotropium Bromide23$28,585
SymbicortBudesonide/Formoterol Fumarate42$18,145
Albuterol Sulfate HfaAlbuterol Sulfate239$8,477
Modafinil82$5,076
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$2,437
Armodafinil43$2,225
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,196
Itraconazole11$1,408
Pramipexole DihydrochloridePramipexole Di-Hcl87$1,342
Prednisone170$775
Ropinirole Hcl61$591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$1,892$322,368254 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,210$74,35986 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$859$72,55871 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Maryville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →